EMIT II Plus Barbiturate Assay
The EMIT® II Plus Barbiturate Assay is intended for the qualitative and semiquantitative analysis of barbiturates in human urine at a cutoff value of 200 ng/mL or 300 ng/mL.
EMIT II Plus Barbiturate Assay
Specific for barbiturates—detects broad class of compounds
Features & Benefits
Barbiturates are a class of nervous-system depressants that are absorbed rapidly and for which 30–40% is bound to plasma protein and the remainder is distributed to muscle, fat, and the liver. They are classified based on their duration of action, ranging from very short-acting (approximately 15 minutes) to long-acting (a day or more). Some of the most commonly abused barbiturates are the short-acting ones, including pentobarbital and secobarbital.
The EMIT II Plus Barbiturate Assay provides:
- High sensitivity to phenobarbital
- Excellent precision—all within-lab (total) CVs ≤0.7% or less across the assay range
- Dual cutoffs available with one assay
- Ready-to-use liquid reagents, calibrators, and controls
- >93% correlation to the reference method
Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.
Technical Specifications
EMIT II Plus Barbiturate Assay Performance
Assay Principle | Homogeneous Enzyme Multiplied Immonoassay (EMIT) |
Cut-off | 200 ng/mL and 300 ng/mL |
Sample | Urine |
Reagent Stability | Unopened until expiration date; Onboard instrument: up to 4 weeks |
Calibration Frequency | As indicated by control results |